Advancing novel therapies for optic neuropathy with a nonhuman primate model
利用非人灵长类动物模型推进视神经病变的新疗法
基本信息
- 批准号:10594226
- 负责人:
- 金额:$ 69.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffectAgeAnatomyAnimal ModelAnimalsApoptosisAutosomal Dominant Optic AtrophyAxonBehavioralBlindnessBreedingCell DensityCell NucleusCell physiologyCellular StructuresCharacteristicsClinicalColor VisionsCommunitiesContralateralDataDendritesDevelopmentDiseaseDisease ProgressionDisease modelDrug KineticsDynaminElectroretinographyEuthanasiaExhibitsEyeFlavoproteinsFluorescenceFunctional disorderFutureGene MutationGenesGeneticGlaucomaGoalsHeritabilityHeterozygoteHistologicHomozygoteHumanImmunohistochemistryIndividualInflammationInheritedInnovative TherapyMacacaMacaca mulattaMeasuresMissense MutationMitochondriaModelingMonitorMorbidity - disease rateMorphologyMultimodal ImagingMutationNerveNerve DegenerationNeurodegenerative DisordersOptic DiskOptic NerveOptic atrophy 1Oxidative StressPallorPathologicPathologyPathway interactionsPatientsPeripheralPersonsPhenotypePhysiologyProductionProtein IsoformsProteinsResearchResolutionResourcesRetinaRetinal ConeRetinal Ganglion CellsScotomaSignal TransductionSpeedTestingThickThinnessTimeTraumaVisionVisualVisual AcuityVisual impairmentachromatopsiaautosomecell injurycohortdensitydifferential expressiondyschromatopsiaeffective therapyhuman tissueimprovedmRNA Expressionmaculamouse modelmultiple omicsneuronal cell bodynew therapeutic targetnonhuman primatenovelnovel therapeutic interventionnovel therapeuticsoptic nerve disorderoptical imagingprogramsprotein expressionretinal imagingretinal nerve fiber layersight restorationtherapeutic evaluationtherapy developmenttranscriptometranscriptomicsvision science
项目摘要
PROJECT SUMMARY
Optic neuropathies are common causes of blindness worldwide, affect the lives of millions, and lack effective
treatments to restore vision. Autosomal dominant optic atrophy (ADOA) is an inherited optic neuropathy that
affects ~3 per 100,000 people worldwide, results in vision impairment, and has no treatment. It is primarily due
to mutations in the optic atrophy 1 (OPA1) gene, which encodes a mitochondrial dynamin-related protein critical
for mitochondrial stability and energy production. A major limitation to the development of effective therapies for
optic neuropathies is the use of animal models that poorly replicate the human condition. Particularly for optic
nerve and RGC disorders, studies would benefit from the use nonhuman primates (NHP) with optic nerve and
retinal anatomy, physiology and pathology, which closely mirrors that of humans. Consequently, well-defined
NHP models of optic neuropathy that are more predictive of human conditions are necessary to efficiently
advance new therapies. We identified rhesus macaques heterozygous and homozygous for a missense mutation
in OPA1 that demonstrate optic nerve head pallor and thinning of the retinal nerve fiber layer in comparison to
wildtype controls; these findings are consistent with ADOA in human patients. We will fully define this NHP model
of ADOA and determine its impact on RGC structure and function longitudinally over a 5-year period. Specifically,
we will assess the onset and progression of retinal dysfunction utilizing electroretinography, retinal flavoprotein
fluorescence and visual testing. Importantly, we will correlate the clinical findings with detailed transcriptomic,
histologic, and immunohistochemical data for a comprehensive characterization of this NHP model of ADOA.
The ADOA transcriptome from NHPs is highly likely to identify novel genes and pathways involved in RGC
pathology and neurodegeneration as well as validate previously implicated pathways thus revealing new
therapeutic targets. We will also perform detailed histological, immunohistochemical and ultrastructural analyses
to assess RGC soma, axons and dendrites as well as their mitochondrial size and number in the macula,
papillomacular bundle, and periphery of the retina. Finally, through selective breeding of ADOA-affected NHPs,
we will generate a supply of macaques heterozygous and homozygous for the OPA1 mutation for future study.
To make this new NHP optic neuropathy model available for therapeutic testing, we propose three Specific Aims:
1) To define the morphologic features and phenotypic spectrum of a NHP model of ADOA, 2) to determine the
impact of the OPA1 A8S mutation on RGC function in NHPs, and 3) to determine mRNA and protein expression
in RGCs of ADOA-affected NHPs. Once the most predictive endpoints of disease and sufficient animals with
ADOA are identified, we will pursue additional studies of etiopathogenesis and novel therapeutic strategies. This
comprehensive NHP model of ADOA will be a highly valuable resource for the vision science and
neurodegenerative disease communities.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sara Michelle Thomasy其他文献
Sara Michelle Thomasy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sara Michelle Thomasy', 18)}}的其他基金
Diversity Supplement: Advancing novel therapies for optic neuropathy with a nonhuman primate model
多样性补充:利用非人类灵长类动物模型推进视神经病变的新疗法
- 批准号:
10844261 - 财政年份:2023
- 资助金额:
$ 69.33万 - 项目类别:
Engineering the Corneal Wound Bed to Promote Healing
设计角膜创面以促进愈合
- 批准号:
8248169 - 财政年份:2011
- 资助金额:
$ 69.33万 - 项目类别:
Engineering the Corneal Wound Bed to Promote Healing
设计角膜创面以促进愈合
- 批准号:
8634787 - 财政年份:2011
- 资助金额:
$ 69.33万 - 项目类别:
Engineering the Corneal Wound Bed to Promote Healing
设计角膜创面以促进愈合
- 批准号:
8450198 - 财政年份:2011
- 资助金额:
$ 69.33万 - 项目类别:
Engineering the Corneal Wound Bed to Promote Healing
设计角膜创面以促进愈合
- 批准号:
8026319 - 财政年份:2011
- 资助金额:
$ 69.33万 - 项目类别:
Engineering the Corneal Wound Bed to Promote Healing
设计角膜创面以促进愈合
- 批准号:
8815316 - 财政年份:2011
- 资助金额:
$ 69.33万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 69.33万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 69.33万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 69.33万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 69.33万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 69.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 69.33万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 69.33万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 69.33万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 69.33万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 69.33万 - 项目类别:
Miscellaneous Programs